Advertisement
An audio webcast of the presentation will be available at the Amicus Website at http://www.amicustherapeutics.com. Participants should allowapproximately five to ten minutes prior to the presentation's start time tovisit the site and download any streaming media software needed to listen tothe webcast. An audio replay of the webcast will also be available on theCompany's Web site for 30 days until October 24, 2008.
Advertisement
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oraltherapeutics known as pharmacological chaperones for the treatment of a rangeof human genetic diseases. Pharmacological chaperone technology involves theuse of small molecules that selectively bind to and stabilize proteins incells, leading to improved protein folding and trafficking, and increasedactivity. Amicus is initially targeting lysosomal storage disorders, which aresevere, chronic genetic diseases with unmet medical needs. Amicus hascompleted Phase 2 clinical trials of Amigal for the treatment of Fabry diseaseand is conducting Phase 2 clinical trials of Plicera for the treatment ofGaucher disease and AT2220 for the treatment of Pompe disease.
FOLD-G
SOURCE Amicus Therapeutics
